119 related articles for article (PubMed ID: 20154404)
1. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Hosoya M; Ohashi J; Sawada A; Takaki A; Shimokawa H
Circ J; 2010 Apr; 74(4):798-806. PubMed ID: 20154404
[TBL] [Abstract][Full Text] [Related]
2. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
4. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
5. Influence of diabetes mellitus, hypercholesterolemia, and their combination on EDHF-mediated responses in mice.
Morikawa K; Matoba T; Kubota H; Hatanaka M; Fujiki T; Takahashi S; Takeshita A; Shimokawa H
J Cardiovasc Pharmacol; 2005 May; 45(5):485-90. PubMed ID: 15821445
[TBL] [Abstract][Full Text] [Related]
6. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Tanifuji C; Suzuki Y; Geot WM; Horikoshi S; Takahashi H; Tomino Y
Kidney Blood Press Res; 2009; 32(4):239-49. PubMed ID: 19752573
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice.
Matoba T; Shimokawa H; Nakashima M; Hirakawa Y; Mukai Y; Hirano K; Kanaide H; Takeshita A
J Clin Invest; 2000 Dec; 106(12):1521-30. PubMed ID: 11120759
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Shinohara K; Hirooka Y; Ogawa K; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
[TBL] [Abstract][Full Text] [Related]
10. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
[TBL] [Abstract][Full Text] [Related]
11. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
12. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
[TBL] [Abstract][Full Text] [Related]
13. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.
Uramatsu T; Nishino T; Obata Y; Sato Y; Furusu A; Koji T; Miyazaki T; Kohno S
Biol Pharm Bull; 2013; 36(8):1271-7. PubMed ID: 23902971
[TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse.
Ding H; Hashem M; Wiehler WB; Lau W; Martin J; Reid J; Triggle C
Br J Pharmacol; 2005 Dec; 146(8):1110-8. PubMed ID: 16231005
[TBL] [Abstract][Full Text] [Related]
15. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
16. Central blood pressure under angiotensin and calcium channel blockade.
Safar ME; Protogerou A; Blacher J
Hypertension; 2009 Oct; 54(4):704-6. PubMed ID: 19667254
[No Abstract] [Full Text] [Related]
17. Effects of angiotensin II receptor antagonist on impaired endothelium-dependent and endothelium-independent relaxations in type II diabetic rats.
Oniki H; Fujii K; Kansui Y; Goto K; Iida M
J Hypertens; 2006 Feb; 24(2):331-8. PubMed ID: 16508581
[TBL] [Abstract][Full Text] [Related]
18. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
19. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
Guo Q; Minami N; Mori N; Nagasaka M; Ito O; Kurosawa H; Kanazawa M; Kohzuki M
Hypertens Res; 2008 Mar; 31(3):525-33. PubMed ID: 18497473
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
